9 results about "Focal segmental glomerulosclerosis" patented technology

Described herein are fusion proteins which include factor H functional domains and may include VHH domains and integrin binding domains, and the use of such fusion proteins in methods of treatment of focal segmental glomerulosclerosis.

Methods for treating primary glomerulonephritis, e.g., focal segmental glomerulosclerosis (FSGS), IgA nephropathy (IgAN) or mesangial proliferative glomerulonephritis (MsPGN) are provided.

Provided herein are methods of treating focal segmental glomerulosclerosis (FSGS), comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. Also provided herein are methods of decreasing renal inflammation and / or fibrosis, reducing the rate of decline in eGFR, delaying the onset of ESKD, decreasing proteinuria, and decreasing fatigue in a subject having FSGS, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to the subject.

The invention discloses application of an SHIP1 agonist AQX-1125 in preparation of a medicine for treating focal segmental glomerulosclerosis, and belongs to the technical field of medicines.The endogenous regulatory factor SHIP1 agonist is used for conducting precise speed limiting on a PI3K / Akt pathway, so that a new effective means is provided for FSGS treatment, and the application form of the SHIP1 agonist AQX-1125 can be an oral preparation and the like; tests prove that the AQX-1125 can remarkably repair renal functions, reduce pathological proteinuria, improve pathological damage of kidney tissues, maintain phenotypic homeostasis and ultrastructural integrity of podocyte and accurately regulate and control pathogenic signal pathways and metabolic homeostasis, so that the AQX-1125 shows remarkable technical progress and clinical application potential in the aspect of FSGS treatment.

Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS) comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I) wherein R1 to R7, A, L, and Y are as defined herein. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I) and their use for the treatment of FSGS.

The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD).

Provided are oligonucleotides, polynucleotide conjugates, and compositions and populations comprising the same, as well as methods and uses thereof for reducing the amount or activity of Rho guanine nucleotide exchange factor 6 (ARHGEF6) RNA in a cell or animal, and in certain instances reducing the amount of ARHGEF6 protein in a cell or animal Such oligonucleotides, polynucleotide conjugates, and compositions and populations, methods and uses are useful to treat kidney diseases or conditions. In particular, such oligonucleotides, polynucleotide conjugates, and compositions and populations, methods and uses are useful to treat chronic kidney disease, such as diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), renal hypertension (HTN), IgA nephropathy / Berger's disease (IgAN), rapidly progressive glomerulonephritis (RPGN) and systemic lupus erythematosus (SLE).

The invention discloses a kit for detecting specific early diagnosis of focal stage glomerulosclerosis, through innovative primer probe design and detection system optimization, the core advantage of the kit is that six miRNA markers, namely miR-125b, miR-186, miR-193a-3p, miR-17, miR-451 and miR-19b, which are verified by a multi-center queue are innovatively integrated; six groups of specific reverse transcription primers based on a stem-loop structure are successfully designed. According to the kit for specific early diagnosis of focal segmental glomerulosclerosis, aiming at the technical defects of low abundance, high sequence homology, poor multi-index detection compatibility and the like of focal segmental glomerulosclerosis (FSGS)-related miRNA, systematic optimization of a stem-loop reverse transcription method and a real-time fluorescent quantitative PCR (qPCR) two-step method is carried out, so that the specificity of the focal segmental glomerulosclerosis is improved, and the specificity of the focal segmental glomerulosclerosis is improved. The detection efficiency, the sensitivity and the specificity are obviously improved.